WebSchinazi is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including Pharmasset Inc., Triangle Pharmaceuticals (acquired by Gilead in 2003), Idenix Pharmaceuticals (51% acquired by Novartis in 2003), and RFS Pharma LLC (formed in Sept 2004). He holds more than 70 US patents. WebMay 12, 2024 · The estimated Net Worth of Raymond F Schinazi is at least Precision BioSciences stock worth over $11,128,692 and over the last 8 years Raymond sold DTIL …
Public funding for transformative drugs: the case of sofosbuvir
Raymond F. Schinazi is an American organic medicinal chemist with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, in… WebAug 20, 2015 · Raymond Schinazi, drug-development pioneer, earns VA's highest honor for biomedical research. August 20, 2015. Dr. Raymond Schinazi, a researcher with the Atlanta VA and Emory University, received VA's 2015 Middleton Award for his development of drugs to treat HIV, hepatitis B, and hepatitis C infections. the pulse shooting orlando
Raymond Schinazi Net Worth, Biography, and Insider Trading
WebSchinazi Raymond F Net Worth 2024 and insider trades. Provides CEO, CFO, Director and Chief Executives trade reports, independent equity research, ... S&P 500 Aggregate Buffett … WebRaymond F Schinazi Currently, there are two safe and effective therapeutic strategies for chronic hepatitis B treatment, namely, nucleoside analogs and interferon alpha (pegylated or non-pegylated). WebDisclamer: Raymond F. Schinazi net worth are calculated by comparing Raymond F. Schinazi's influence on Google, Wikipedia, Youtube, Twitter, Instagram and Facebook with … the pulse sbghc